Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05930145

Results of the Use of Two Stentrievers Simultaneosly Compared With One as a Primary Treatment in Acute Ischemic Stroke

Several studies have demonstrated that simultaneous treatment with two stentrievers (STs) as rescue treatment is very effective, with high recanalization rates even in this group of patients where other revascularization techniques have failed. There has been no observed increase in hemorrhagic complications. Recently, a prospective study has been published where treatment with two ST has been shown to be effective and safe if used as a first-choice treatment (not as rescue) with a successful recanalization rate (eTICI 2c/3) after the first pass of 69%. These results have been reinforced after the publication of a randomized study that confirms, in vitro, the superiority of using two ST over one.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Stroke Arterial Occlusive Diseases Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Nervous System Diseases Thrombectomy Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Alfried Krupp Hospital Ruettenscheid, Essen, Germany

Loading trial locations.

About this study

The use of a double stent retriever has been proposed as a safe and effective technique. The investigators hypothesized that the use of double stentriever primary could lead to higher first pass effect rates and better outcomes compared to single stentriever primary.

Our goal is to develop a research project to provide additional information on the potential benefits of the simultaneous double stent approach primarily in stroke patients receiving endovascular treatment.

A randomized study to compare the efficacy of double primary stentriever versus single primary stentriever.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A new disabling focal neurological deficit compatible with acute cerebral ischemia.
  • Any age. Informed consent obtained from the patient or representative.
  • NIHSS score ≥ 6.
  • Pre-existing functional clinical status less than or equal to 2 according to the mRS clinical scale.
  • Maximum time of 24 hours from symptom onset to arterial puncture. • TICI 0-1 in the diagnosed TICA (terminal internal carotid artery) , MCA (middle cerebral artery), and BA( basilar artery confirmed by angioCT and angiography).
  • ASPECTs score on baseline CT greater than or equal to 6.
  • In cases where it is indicated, prior intravenous fibrinolysis will be administered according to the protocols of each center.

Exclusion criteria

  • Those described in the usual protocols for mechanical thrombectomy of each hospital.
  • Pre-existing functional clinical status greater than 2 according to the mRS clinical scale
  • Patients with tandem lesions of dissection or arteriosclerotic origin located in the extracranial internal carotid artery.
  • Initiation of treatment with a different technique than the one described.
  • Inability to use a proximal balloon guide catheter.
  • Use of aspiration catheter.
  • Intracranial atherosclerotic plaque as the cause of occlusion.
  • Advanced or terminal disease with a life expectancy of less than 6 months.
  • Patient who is participating in another study that may affect this one.
  • ASPECTS score less than or equal to 6 on baseline CT.
  • Evidence of significant hemorrhage or mass effect with midline shift on baseline CT.
  • Patients with occlusions in multiple vascular territories.
  • Evidence of intracranial tumor (except for small meningiomas)

Treatment and study plan

Double stentriever

Device

Double stentriever technique

Single stentriever

Device

Single stentriever technique

Primary outcomes

  1. EFFECTIVENESS OBJECTIVE: Complete recanalization on first pass

    Time frame: 90 days

    Comparison of the complete recanalization rate in the first pass in the double stent group compared to the single stent group, defined as TICI greater than 2c on the Thrombolysis in Cerebral Infarction scale (eTICI scale).

  2. SAFETY OBJECTIVE: Intracerebral hemorrhage.

    Time frame: 24 hours

    Rate of patients with symptomatic intracranial hemorrhage (neurological deterioration in National Institutes of Health Stroke Scale [NIHSS] >4) at 24h observed between both groups and, fundamentally, evaluated by CT.

Secondary outcomes

  1. Intervention success.

    Time frame: During the procedure

    Rate of the ability to position both STs in the indicated location.

  2. Complications related to the intervention.

    Time frame: During the procedure

    Evaluation of the rate of arterial perforation, angiographic extravasation of contrast, arterial dissection or arterial vasospasm.

  3. Embolism in new territories.

    Time frame: During the procedure

    Rate of embolization to an artery not involved in the initially affected territory.

  4. Number of passes with the devices.

    Time frame: During the procedure

    Evaluation of the number of passes with the devices during the procedure.

  5. Procedure time.

    Time frame: During the procedure

    Time from arterial puncture to arterial recanalization, or if not achieved, until the end of the intervention.

  6. Arterial Recanalization (eTICI scale) on first pass.

    Time frame: During the procedure

    evaluation of the rates of eTICI 3, eTICI 2c/3, eTICI e2b/3 on the Thrombolysis in Cerebral Infarction scale (e TICI scale); range 0-3, with highest score indicating complete recanalization.

  7. Arterial recanalization at the end of the procedures.

    Time frame: During the procedure

    eTICI 3, eTICI e2c/3, eTICI e2b/3 at the end of the procedure on the Thrombolysis in Cerebral Infarction scale (e TICI scale); range 0-3, with highest score indicating complete recanalization.

  8. Intracerebral hemorrhage.

    Time frame: 24 hours

    Rate of any type of intracranial hemorrhage on the 24-hour control computed tomography (CT) scan (subarachnoid hemorrhage and hemorrhage according to the classification used in the ECASS study).

  9. Early neurological improvement.

    Time frame: 24 hours

    Rate of patients with a decrease of 10 points or more on the NIHSS scale or complete recovery during the first 24 hours. Improvement of Neurological status at 24 hours, determined by National Institutes of Health Stroke Scale [NIHSS score] range 0-42, with higher scores indicating greater stroke severity.

  10. National Institutes of Health Stroke Scale (NIHSS) scale at 24 hours, on day 5, or at discharge.

    Time frame: 5 days

    Neurological status at 24 hours, at day 5 (+/- 12 hours) or discharge, determined by National Institutes of Health Stroke Scale [NIHSS score] range 0-42, with higher scores indicating greater stroke severity.

  11. Modified Rankin Scale (mRS) scale at 90 days.

    Time frame: 90 days

    Modified Rankin Scale (mRS; range 0 [no symptoms] to 6 [death] for the evaluation of neurological functional disability score at 90 days

  12. Mortality rate.

    Time frame: 90 days

    90-day mortality rate.

Study contacts

Contact information is provided by the study sponsor or research team.

PEDRO VEGA VALDES, MD, PhD

CONTACT

[email protected]

0034985108000 ext. 39116

Sponsors and collaborators

Lead sponsor

Fundación EPIC

Other

Registry information

Official study title

A Randomized Study Comparing the Effectiveness and Security of the Use of Two Stentrievers Simultaneously Versus One Stentriever as a Primary Treatment in Acute Ischemic Stroke Patients.

Acronym: DIVERSO

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 5, 2023
Registry last updated
Jul 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.